Affas, Ziad and Touza, Ghaid and Touza, Rowaid and Affas, Saif and Azzo, Zain and Shakir, Ali (2022) Mavacamten a Novel DiseaseSpecific Treatment for Hypertrophic Obstructive Cardiomyopathy: A Meta-Analysis and Systematic Review. In: Current Innovations in Medicine and Medical Science Vol. 2. B P International, pp. 114-128. ISBN 978-93-5547-866-5
Full text not available from this repository.Abstract
The purpose of this study was to conduct a systematic evaluation and outcome assessment of published and on-going studies of mavacamten therapy to treat Hypertrophic cardiomyopathy (HCM). HCM is a common genetically based cardiac disease with an estimated prevalence of 1 in 200-500 cases that poses a significant threat to young adults and athletes. Sequence differences in numerous genes that encode proteins for the thick and thin cardiac myofilaments, which are in charge of causing the heart sarcomere to contract, are the genetic basis for HCM. Hypertrophic cardiomyopathy is spread in an autosomal dominant manner by pathogenic mutations. Hypertrophic cardiomyopathy is typically divided into obstructive (approximately 70%) and non-obstructive subtypes. Clinical manifestation of HCM can range from asymptomatic to drug-refractory advanced heart failure. Mavacamten is a first-in-class myosin inhibiting drug that has progressed through in vitro studies. It has shown promising results in patients with symptomatic hypertrophic obstructive cardiomyopathy.
The databases PubMed, EMBASE, Clinicaltrials.gov, and Medline were searched with keywords for the existing literature on mavacamten for treating HCM. Cross-referencing was used to determine the eligibility of retrieved articles and to identify biases.
A total of 1066 studies were found in an initial keyword search. These articles were then subjected to an eligibility criterion to ensure relevance to the review objectives. Stratification of possible publications identified 9 studies for inclusion in the review, including randomized clinical trials, Clinical Trials, and ongoing Trials. A meta- analysis of probable mavacamten outcomes was then undertaken using the Cochrane Meta-analytic Tool, with the results visualized as forest plots and a narrative table. Treatment of symptomatic obstructive cardiomyopathy with mavacamten significantly impacted primary outcomes, such as improved left ventricular obstruction tract gradient and increased peak oxygen consumption, as well as secondary outcomes, such as improved exercise resilience, reduced NYHA classes, increased life-years, and improved overall quality of life. Myosin-inhibitors may be used as alternative treatment interventions for symptomatic HOCM patients in the short term and possibly in the long term, as suggested by the significant benefits associated with mavacamten therapy for HCM patients, including improved quality of life and an increase in life years.
Item Type: | Book Section |
---|---|
Subjects: | GO for ARCHIVE > Medical Science |
Depositing User: | Unnamed user with email support@goforarchive.com |
Date Deposited: | 11 Oct 2023 05:26 |
Last Modified: | 11 Oct 2023 05:26 |
URI: | http://eprints.go4mailburst.com/id/eprint/1275 |